Here’s a summary of the key takeaways from the article, focusing on the treatment of geographic Atrophy (GA):
* Current Treatments: Pegcetacoplan and avacincaptad pegol are currently approved treatments for GA, but patient compliance can be a challenge due to the monthly/bimonthly injection schedule and the fact that these drugs preserve vision rather then improve it.
* Challenges with Current Treatments: Side effects like intraocular inflammation and injection-related volume changes are also considerations.
* Future Treatments: Research is ongoing into visual cycle modulation, cell therapy, and neuroprotection as potential future GA treatments. Vonaprument (Annexon Biosciences) and elamipretide (Stealth BioTherapeutics) are therapies in growth.
* Urgency of Current Treatment: The speaker (Singh) strongly encourages retina specialists to utilize the FDA-approved treatments now, as new drugs aren’t expected to be available until 2028 or beyond.He advises against waiting to begin treatment.
* Source: The details was presented at the Retina 2026 conference by Dr. Singh.
* Disclosure: Dr. Singh has financial ties to several pharmaceutical companies involved in GA treatments (Alcon, Apellis, Bausch + Lomb, etc.).
